Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ellume CEO Ponders Future Of Company’s Rapid COVID-19 Antigen Test

Executive Summary

The developer of the at-home over-the-counter antigen test — the first of its kind to get an emergency use authorization from the FDA – received more than $200m from the government to manufacture in the US. So what’s next for Ellume? In this Medtech Insight case study Q&A, the Australian company’s CEO, Sean Parson, explains.

You may also be interested in...



Digital Health Roundup, March 2021: Record-Breaking Funding; Exec Chats With Medtronic, Edwards LifeSciences

In this new roundup feature focusing on the most notable developments in digital health, we pick the key news to date.

Biden Admin Pays Ellume $231M To Build COVID-19 US Test Plant

The government seems to be betting the company’s over-the-counter at-home antigen diagnostic test will be a game changer in stopping the spread of the coronavirus.

FDA Official: Uptick In PMA, 510(k) Applications Calls For More User Fee Dollars

The number of PMA and 510(k) applications have been steadily growing and becoming harder to review as they’ve become more complex – which an FDA official says means the agency needs more financial resources.

Topics

UsernamePublicRestriction

Register

MT143738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel